An adaptive response is a response to a stress such as radiation exposure that results in a lower than expected biological response. We describe an adaptive response to X radiation in mouse prostate using the pKZ1 chromosomal inversion assay. pKZ1 mice were treated with a priming dose of 0.001, 0.01, 1 or 10 mGy followed 4 h later by a 1000-mGy challenge dose. All priming doses caused a similar reduction in inversions compared to the 1000-mGy group, supporting the hypothesis that the adaptive response is the result of an on/off mechanism. The adaptive response was induced by a priming dose of 0.001 mGy, which is three orders of magnitude lower than has been reported previously. The adaptive responses completely protected against the inversions that would have been induced by a single 1000-mGy dose as well as against a proportion of spontaneous background inversions. The distribution of inversions across prostate gland cross sections after priming plus challenge irradiation suggested that adaptive responses were predominantly due to reduced low-dose radiation-induced inversions rather than to reduced high-dose radiation-induced inversions. This study used radiation doses relevant to human exposure. ᭧
INTRODUCTION
High-dose X radiation is a mutagen and carcinogen, but the harmful effects of low-dose X radiation (Ͻ100 mGy) are less clear. It is known that gene expression patterns are different after low-dose radiation exposure compared to high-dose exposure (1, 2) . Also, at very low doses, the bystander effect can play a role whereby cells do not require a direct ionizing radiation event to produce biological effects (3) . An adaptive response is a response to an external stress, such as radiation, that is modified by prior exposure to the same or a different stress and results in a lower than expected biological response (4) . The interplay between adaptive response and bystander effects, together with other factors such as dose rate, cell type and genomic instability (5) , influences the net biological effect of lowdose irradiation. The adaptive response is incompatible with the linear, no-threshold (LNT) model, which assumes an incremental increase in risk with any dose above background, and warrants further investigation. An understanding of the adaptive response may have implications for radiation protection strategies.
An adaptive response can be measured in biological systems using either single or multiple (priming plus challenge) dose regimens. An adaptive response in a singledose treatment regimen manifests as a reduction in the end point under investigation to a level below the spontaneous frequency. Using a two-dose treatment regimen (low priming dose followed by high challenge dose), an adaptive response can be detected as a decrease in the end point under investigation after exposure to both doses compared to exposure to a single high dose alone. In two-dose radiation studies, Olivieri et al. (6) demonstrated an adaptive response for chromosomal aberrations in human lymphocytes using a low priming dose of tritiated deoxythymidine prior to a high challenge X-radiation dose. Adaptive responses have been induced in mammalian cells by two-dose protocols for end points including chromosome breaks (7, 8) , mutations at the hypoxanthine-guanine phosporibosyltransferase (HPRT ) locus (9) (10) (11) (12) , micronucleus formation and neoplastic transformation (13) (14) (15) , chromosomal aberrations (16) , apoptosis (17) , and increased tumor latency in mice (18) . Mutation adaptive responses induced by low single radiation doses, which result in a reduction in the mutation frequency to below the spontaneous frequency, have been difficult to detect because many mutation assays lack the required sensitivity. However, adaptive responses have been reported in vitro after single low-dose irradiation with doses between 1-100 mGy, which resulted in a reduction of the neoplastic transformation frequency to below the endogenous frequency (19, 20) .
The pKZ1 mouse recombination assay is exquisitely sensitive for detecting changes in chromosomal inversion frequency after in vivo exposure to single low X-radiation doses. A nonlinear dose response for chromosomal inversions in pKZ1 mouse spleen and prostate has been reported previously for X-radiation doses in the range of 0.001-2000 mGy (21, 49) . In these studies, an induction of inversions was observed at high doses of X radiation of 1000 mGy or above. In the 1-10 mGy dose range, a reduction of the inversion frequency to below the inversion frequency in sham-treated mice was observed, whereas a net increase in inversion frequency was observed in the 0.005-0.01-mGy ultra-low-dose range. The reduction in inversion frequency to below the frequency in sham-treated mice in the 1-10-mGy low-dose range is suggestive of an anti-mutagenic effect that is likely mediated by host responses involving the induction of endogenous radioprotective factors. Conversely, the increase of inversions in the 0.005-0.01-mGy ultralow-dose range suggests that such low doses are more mutagenic than doses in the 1-10-mGy region. These results contradict the LNT model and challenge conventional risk assessment in human populations that may be exposed to radiation doses in the range of 0.001-10 mGy, for instance from diagnostic medical exposures. It is particularly important to study doses in the 0.005-0.01-mGy range, where risk assessment based on the LNT model may underestimate the mutagenic effects. The ultra-low-, low-and highdose regions of the radiation inversion dose response in pKZ1 mouse tissues suggest that different biological responses are induced at different doses. In the work described here, adaptive response studies were performed to determine whether priming X-radiation doses from the different regions of the nonlinear dose response measured by the pKZ1 chromosomal inversion could induce protection from the effects of a subsequent high X-radiation dose, or whether the doses would be additive.
MATERIALS AND METHODS

pKZ1 Transgenic Mice
The pKZ1 transgenic construct was developed by Matsuoka et al. (22) . The construct has the E. coli lacZ gene in an inverse transcriptional orientation relative to a chicken ␤-actin enhancer-promoter (EP) complex. Inversions in the transgene are facilitated by mouse recombination signal sequences flanking the lacZ gene and place the lacZ gene in the correct transcriptional orientation to the EP complex, resulting in expression of the lacZ gene product, ␤-galactosidase (␤-gal). The pKZ1 founder was an F 2 C57BL/6J ϫ DBA2 mouse. All progeny were backcrossed to C57BL/6J mice to produce mice heterozygous for the pKZ1 transgene. Mice were barrier maintained in micro-isolators in the Flinders Medical Centre Animal House and were fed stock ration (Ridley Agriproducts, Adelaide, South Australia). Quality control for viruses, parasites and bacteria was performed quarterly, and all mice tested were negative. Progeny from the pKZ1 colony were screened for the presence of the pKZ1 transgenic construct using DNA from tail clippings and an E. coli LacZ specific PCR (23) . The natural background radiation to which the mice were exposed during their normal living conditions was approximately 2 mSv/ year. All experiments were approved by the Flinders University and the Royal Adelaide Hospital/Institute of Medical and Veterinary Science Animal Ethics Committees.
X Irradiation of Mice
A description of the X-ray exposure system and dosimetry has been published previously (21) . Briefly, treated transgenic and nontransgenic pKZ1 mice were restrained in individual compartments in a 6-mm-thick Perspex holder and irradiated with a whole-body dose of X rays using an Orthovoltage deep X-ray radiation therapy unit (250 kV, 15 mA) located at the Royal Adelaide Hospital Radiotherapy Facility, Adelaide. The desired dose was achieved through variation in treatment time, lead filters and source-to-mouse distance. Independent dosimetry was performed for doses of 1 mGy or less using a Victoreen 450P survey meter. The overall uncertainty of dose delivery was conservatively estimated to be Ϯ20%, which is well below the orders of magnitude differences in dose that were studied. Mice were exposed to a single priming dose of 10 (dose rate 13.9 mGy/min), 1 (dose rate 0.34 mGy/min), 0.001 or 0.01 mGy (dose rate 0.0014 mGy/min), followed 4 h later by a challenge dose of 1000 mGy (dose rate 180 mGy/min). Sham-treated transgenic and sham-treated nontransgenic pKZ1 mice were used as controls. For logistical reasons and to minimize the number of mice required in this study, each treatment group comprised mice that were irradiated on different days and pooled for screening and analysis.
Histochemical Analysis of Inversions in pKZ1 Mouse Prostate
The method for histochemical detection of inversions in the pKZ1 mouse prostate has been described previously (24) . Mice were killed humanely by CO 2 asphyxiation 3 days after treatment, and prostate tissue was removed, embedded in OCT cryoprotectant (Tissue-Tek), and snap frozen. Frozen prostate sections (5 m) were fixed in glutaraldehyde on slides, stained for 4 h with X-gal, and counterstained with neutral red. Slides were dehydrated with ethanol and xylene, and cover slips were mounted with DPX mounting medium (BDH Laboratories, UK). Sections from a pKZ1 transgenic mouse brain, which stain brightly for E. coli ␤-gal activity, were included as a positive staining control, and prostate tissue sections from nontransgenic mice were included as negative staining controls. Tissues were screened at 500ϫ magnification using an Orthoplan microscope (Leitz, Germany). The number of luminal epithelial cells and the number of inversions were scored for 50 prostate gland cross sections from each mouse (Fig. 1 ). Only gland cross sections that contained at least 50 luminal epithelial cells were analyzed. The inversion frequency was calculated by dividing the number of luminal epithelial cells with staining indicative of an inversion by the total number of luminal epithelial cells in the same 50 prostate gland cross sections. Slides were coded by another individual and screened blind to eliminate observer bias.
Calculation of Inversion Frequency and Statistical Analysis
Occasionally nonspecific staining was scored in nontransgenic prostate tissue. To account for nonspecific staining, the corrected inversion frequency for each transgenic mouse treatment group was determined by subtracting the mean nonspecific staining frequency in nontransgenic treated mice. Designed contrasts between the corrected inversion frequency in the sham-treated group and each radiation treatment group were performed using a two-tailed Mann-Whitney U test. Similarly, planned comparisons were made between the corrected inversion frequency in each priming plus challenge group and the 1000-mGy challenge alone group using a two-tailed Mann-Whitney U test. The magnitude of the adaptive response was determined by where the corrected inversion frequency (CIF) is the mean inversion frequency in transgenic mice minus the mean frequency of nonspecific staining in nontransgenic mice that received the same treatment. The distribution of the number of inversions in gland cross sections in transgenic mice was also corrected for nonspecific staining. This was achieved within each treatment group by subtracting the median number of nontransgenic mouse gland cross sections with each number of blue staining cells (one, two or three) from the number of transgenic gland cross sections with the same number of blue-staining cells. The effect of treatment on the distribution of inversions in gland cross sections was assessed using a Kolmogorov-Smirnov test. For each transgenic mouse treatment group, the predicted distribution of inversions in gland cross sections was calculated based on an expected Poisson distribution of inversions across gland cross sections using the mean number of inversions per gland cross section. The total number of luminal epithelial cells scored in each group and correlations between the number of inversions and the number of luminal epithelial cells in each gland cross section was analyzed by univariate ANOVA. The statistical significance threshold was assigned at P Յ 0.05. Statistical analyses were performed using SPSS for Windows, Version 12.0.1 (SPSS Inc.).
RESULTS
Chromosomal Inversion Adaptive Response in pKZ1 Prostate
The observed and corrected inversion frequencies for each treatment group and statistical analyses are shown in Table 1 . Figure 2 is a graphical representation of the inversion frequencies in each transgenic and nontransgenic mouse group. There were at least five transgenic and two nontransgenic mice in each treatment group. Nonspecific staining was rare in sham-treated (0 mGy) nontransgenic mice (0.07 Ϯ 0.04 ϫ 10
Ϫ3
, n ϭ 5) and in nontransgenic mice treated with a single low dose in the range of 0.001-10 mGy (mean frequency for all groups, 0.15 Ϯ 0.03 ϫ 10
, n ϭ 11). The frequency of nonspecific staining in nontransgenic mice was higher after a single dose of 1000 mGy (1.38 Ϯ 0.44 ϫ 10 Ϫ3 ) or after any of the priming plus challenge treatments (mean frequency for priming plus challenge groups, 1.76 Ϯ 0.26 ϫ 10 Ϫ3 , n ϭ 14). There was a significant 130% or 200% induction in corrected inversion frequency after single-dose treatment with 0.01 or 1000 mGy, respectively (P ϭ 0.04 in both cases, two-tailed Mann-Whitney U test). There was a significant reduction in the corrected inversion frequency to 40% (P ϭ 0.005) and 42% (P ϭ 0.003) below the corrected inversion frequency for sham-treated mice after a single dose of 1 or 10 mGy, respectively. Treatment with 0.001 mGy did not result in a significant change from sham-treated mice in the corrected inversion frequency in prostate.
A significant adaptive response for chromosomal inversions was induced by priming doses of 0.001, 0.01, 1 or 10 mGy delivered 4 h prior to a challenge dose of 1000 mGy. The inversion adaptive response resulted in complete protection against the inversions that would have been induced by a 1000-mGy challenge radiation dose as well as protection against a proportion of endogenous inversions. The magnitude of the adaptive response (calculated using the formula described in the Materials and Methods) in- Notes. * Statistically significant (P Ͻ 0.05) compared to the sham-treated group; ** statistically significant (P Ͻ 0.05) compared to the 1000-mGy group (two-tailed Mann-Whitney U test). Percentage change was calculated as the difference between (T-NT) after each treatment. Single doses were compared to the sham-treated group, and adaptive groups were compared to both sham-treated and challenge (1000 mGy) groups. ↓: reduction in corrected inversion frequency; ↑: induction in corrected inversion frequency; both relative to the sham-treated group.
a T: transgenic; NT: nontransgenic. b T-NT inversion frequency is the corrected inversion frequency on which inter-radiation treatment group comparisons and statistical analyses were performed.
c The prostate inversion frequency for these groups is reported elsewhere (49).
FIG. 2.
Mean uncorrected inversion frequency (Ϯ SE) in pKZ1 mouse prostate after priming ϩ challenge whole-body X irradiation. T: transgenic; NT: nontransgenic. 5 Յ n Յ 10 transgenic mice, and 2 Յ n Յ 5 nontransgenic mice. *Significant change in corrected inversion frequency between sham-treated and treated mice. **Significant change in corrected inversion frequency between priming ϩ challenge and challenge only groups. P Ͻ 0.05, two-tailed Mann-Whitney U test. Corrected inversion frequencies are shown in Table 1 and were calculated by subtracting frequencies for nontransgenic mice from those for transgenic mice to correct for nonspecific staining.
duced by priming doses of 0.001, 0.01, 1 or 10 mGy prior to a challenge dose of 1000 mGy was 167, 144, 134 and 165%, respectively. There were no significant differences between the magnitudes of the adaptive responses induced by any of the priming doses studied (P ϭ 0.432, Univariate ANOVA). The corrected inversion frequencies in the 0.001-, 0.01-, 1-and 10-mGy priming plus challenge groups were 67, 40, 34 and 66% below the corrected inversion frequency in the sham-treated group (P ϭ 0.001, 0.05, 0.06 and 0.005, respectively).
Distribution of Inversions in Prostate Gland Cross Sections
There was no correlation between the number of luminal epithelial cells and the number of inversions per gland cross section in sham-treated transgenic mice (P ϭ 0.228, univariate ANOVA). The mean (Ϯ SE) number of luminal epithelial cells screened per mouse in 50 gland cross sections for all mice studied (n ϭ 110) was 5.30 Ϯ 0.06 ϫ 10 3 (range 4.08-7.47 ϫ 10 3 ). There was no significant difference in the total number of luminal cells screened in 50 prostate gland cross sections in any of the treatment groups (P ϭ 0.147, univariate ANOVA). The maximum number of inversions per gland cross section varied after treatment with single radiation doses ranging between 0.001 and 1000 mGy. There were 0-7 inversions per transgenic mouse prostate gland cross section and 0-3 staining events per gland cross section in nontransgenic or sham-treated transgenic mice. In Table 2 , the number of glandular cross sections with a specified number of inversions is expressed as a percentage of the total glandular cross sections scored in each treatment group. The maximum number of staining events per gland cross section was always higher in the transgenic than the nontransgenic group for each treatment group. In transgenic mice, the distribution of the number of inversions per gland cross section did not follow a Poisson distribution for the 0.01-mGy and 1000-mGy groups (Kolmogorov-Smirnov test, P Ͻ 0.05). The distribution of the number of inversions per gland cross section did follow a Poisson distribution for all other groups (Kolmogorov-Smirnov test, P Ͼ 0.05), indicating that in these groups, the inversions scored were rare, random and independent. There was no significant difference between the observed distribution of inversions in prostate gland cross sections in the sham-treated, 1-mGy and 10-mGy groups compared with the theoretical Poisson distribution based on the total number of inversions scored in each treatment group ( 2 , P Ͼ 0.90). There was a significant difference between the observed distribution of inversions in gland cross sections compared to the predicted Poisson distribution for the 0.001-mGy group (P ϭ 0.05). The distribution of inversions in gland cross sections was significantly different to the expected Poisson distribution for each of the priming plus challenge groups (P Ͻ 0.001). Representative data are presented for treatment groups for which there was no significant difference between the observed distribution of inversions across prostate gland cross sections and the predicted Poisson distribution [sham-treated (Fig. 3A ) and 1 mGy (Fig. 3B) ], for the 1000-mGy group (Fig. 3C) , and for a priming plus challenge group, for which the distribution of inversions across gland cross sections was significantly different to the predicted Poisson distribution [1 mGy followed by 1000 mGy (Fig. 3D) ].
DISCUSSION
Single low doses of X radiation in the 1-10-mGy range have been shown to induce an adaptive response for chromosomal inversions in pKZ1 mouse spleen (21) and prostate (49) by reducing the inversion frequency to below the spontaneous inversion frequency. The aim of the present study was to use two-dose adaptive response experiments to investigate whether priming radiation doses of 10 mGy or lower could induce an adaptive response that would protect from chromosomal inversions induced in pKZ1 prostate by high challenge radiation doses. Analysis of inversions was performed 3 days postirradiation in this study to maintain consistency with our previous studies of low-dose X-radiation responses in the pKZ1 mouse spleen (21) and prostate (49) . The regions of the dose-response curve that were selected for priming doses were the low-dose region (1 and 10 mGy), and two ultra-low doses (0.01 and 0.001 mGy). Single 1-or 10-mGy doses of X radiation caused a reduction in the corrected inversion frequency to below the frequency in sham-treated mice in prostate, confirming results in the pKZ1 mouse assay at these doses (49) . This suggests that doses of 1-10 mGy induce radioprotective factors. It was therefore expected that priming doses in the region of 1-10 mGy would induce adaptive responses if subsequently followed by a challenge with a higher radiation dose. In contrast, a single dose of 0.01 mGy caused an increase in corrected inversion frequency, suggesting that an additive response, rather than an adaptive response, may be observed if a subsequent high challenge dose is administered. A single dose of 0.001 mGy had no significant effect on the corrected inversion frequency, which may indicate that it was too low to induce radioprotection. However, all priming doses between 0.001-10 mGy resulted in the induction of an adaptive response for chromosomal inversions when subsequently challenged with a high dose of 1000 mGy, suggesting that all of the priming doses studied induced radioprotective factors. Although all priming doses were able to protect from inversions induced by a 1000-mGy dose, the single priming doses alone between 0.001-0.01 mGy had less ability to reduce chromosomal inversions to below the spontaneous frequency compared to the radioprotective signals induced by 1-10 mGy. The induction of an adaptive response by priming doses in the 1-10-mGy dose range was in agreement with a previous study that used a two-dose adaptive response protocol. Broome et al. (25) demonstrated an adaptive response for micronucleus induction in human fibroblasts using priming doses of 1 mGy or greater prior to a high challenge dose of 4000 mGy. The induction of an adaptive response for chromosomal inversions by a priming dose of 0.001 mGy in the present study extends the known priming dose range for an adaptive response by three orders of magnitude.
Both the dose and dose rate are important determinants of radiation responses. At a dose of 1 mGy delivered at 250 kVp in the present study, each cell nucleus receives on average a single ''hit'', which is the energy imparted by a single electron track (26) . As the radiation dose decreases, the fraction of cells that receive a radiation hit decreases to approximately 0.1% at the lowest dose used here (0.001 mGy); the energy imparted to the individual hit cells does not change. At radiation doses of 10 mGy and above, both the fraction of cells that receive a radiation hit and the energy imparted to each hit cell increase. In the present study, the adaptive response was similar in magnitude after priming doses of 0.001-10 mGy despite large differences in energy deposition in individual cells within this range of priming doses. This supports previous studies that show that the passage of an ionizing event through a cell nucleus is not required for the induction of an adaptive response (27) (28) (29) and in turn suggests that bystander signaling is important in the induction of an adaptive response. The proliferative and apoptosis indices of adult mouse prostate luminal epithelial cells are approximately 0.1% (30) , and therefore the observed inversion frequency in the prostate is unlikely to be the result of turnover of hit luminal epithelial cells in the 3 days between irradiation and scoring of inversions. All radiation doses in this study were delivered over an acute period of 0.7-7 min. Even at the lowest dose studied here (0.001 mGy), the dose was delivered at a dose rate that was approximately 300 times higher than the background dose rate. This increased dose rate would result in a radiation hit to approximately 1/2,000 cells per 763 ADAPTIVE RESPONSE IN MOUSE PROSTATE minute, compared to approximately 1/700,000 cells that would receive a hit each minute from natural background radiation. The induction of an adaptive response by a 0.001-mGy priming dose suggests that increasing the fraction of hit cells for a short time can result in sufficient bystander signaling from hit cells to induce an adaptive response in the whole tissue. In the present study, all priming doses between 0.001-10 mGy were equally effective in the induction of an adaptive response for chromosomal inversions to a subsequent high challenge dose, despite different priming dose rates ranging from 0.0014-13.9 mGy/min. These results suggest that dose rates within this range for low priming doses do not affect the induction of an adaptive response. Other studies in the literature have only investigated dose-rate effects for high total radiation doses (17, 31) .
The lead shielding that was used to reduce the dose rate at the lower doses in this study and in a previous study (21) changed the radiation energy spectrum by blocking the passage of low-energy photons, resulting in a radiation beam with a higher average energy than the beam at doses of 10 mGy and higher. It has been shown that in the dose range 500-3000 mGy, the yield of DNA strand breaks is similar between radiations with energy spectra of 29 kVp, 220 kVp and 1.2 MeV ( 60 Co ␥ radiation), although the fidelity of DNA repair is lower after exposure to low-energy radiation (32, 33) . In contrast, in a similar dose range, it has also been shown that in the low-energy spectra range from 10-60 kVp, lower-energy radiation is more effective in inducing chromosome aberrations or micronuclei than higher-energy radiation (34) . In the present study, although the proportion of low-energy photons was reduced at doses of 1 mGy or lower, relative to higher doses, the induction of an adaptive response by all priming doses in the range 0.001-10 mGy suggests that the biological effectiveness of different radiation spectra in the induction of chromosomal inversions was similar.
No correlation was observed between the magnitude of the priming dose and the magnitude of the adaptive response in the pKZ1 mouse prostrate, as measured by chromosomal inversion frequency. This is in agreement with the only other report of the effect of a range of priming doses between 1-500 mGy on the magnitude of the adaptive response, measured using a high challenge dose of 4000 mGy (25) , and suggests that the adaptive response is an all-ornone process rather than a dose-dependent one. The adaptive responses observed in the pKZ1 mouse prostate resulted in complete protection from chromosomal inversions that would have been induced by a 1000-mGy challenge dose as well as some protection from spontaneous inversions. This is equal to an adaptive response with a magnitude of greater than 100%, which is a larger effect than has been reported for any end point. Adaptive responses usually confer 20-50% protection from induced mutations such as micronuclei and chromosome aberrations (25, 35, 36) , although up to 70% protection from induced mutations at the HPRT locus has been reported (10) . The present study is the first to demonstrate an adaptive response showing protection against a challenge dose and additional protection to below the spontaneous frequency. The mechanisms underlying the large magnitude of adaptive response observed here in the pKZ1 mouse prostate are unknown, but they may be due to (1) the assay being inherently sensitive to modulation of inversion frequency by radiation, (2) the timing between the priming and challenge irradiation or between challenge and sampling, or (3) tissue-type differences in the adaptive response. Tissue-specific radiation sensitivity is well established after high-dose radiation exposure. Little is known about tissue-specific radiation responses after low-dose radiation exposure or in a twodose adaptive response setting. Our previous studies have shown a similar chromosomal inversion response in pKZ1 mouse spleen and prostate after single low-dose radiation exposure (21, 49) , which suggests that tissue-specific differences may not be of major importance after low-dose radiation exposure. Also, since our data and those from other studies suggest an on-off mechanism of adaptive response, it is likely that when an adaptive response is induced, the magnitude of the response will not vary with time between the priming and challenge irradiation. The time of analysis postirradiation may be more important. We have analyzed tissues for inversions in this and our previous studies at day 3 postirradiation (21, 49) . The pattern of hormetic dose response observed in these studies is similar to that observed at one time predicted by a direct stimulation hormetic response [reviewed in ref. (37) ]. The direct stimulation hormetic response predicts that the magnitude of response will vary with time. Experiments where the inversion frequency in pKZ1 mice is analyzed on different days postirradiation are required to investigate the temporal nature of the magnitude of the adaptive response.
We do not believe that the magnitude of the adaptive response in the present study was due to the high frequency of nonspecific staining in prostate from mice exposed to a 1000-mGy dose, whether as a single or challenge dose after a priming irradiation. Nonspecific staining was observed in nontransgenic mouse prostate after high-dose irradiation, despite performing histochemical staining at a pH that was selective for the activity of E. coli transgene-specific ␤-gal rather than mammalian lysosomal ␤-gal. Nonspecific staining has been reported after single X-radiation doses in nontransgenic C57BL/6J mouse prostate and spleen (38, 39, 49) . The mechanism underlying radiation-induced ␤-gal staining in nontransgenic mice is unclear, although it has been linked to the clearance of apoptotic cells (40) . Both apoptosis (41) and necrosis are induced by high-dose radiation; however, ␤-gal is not expressed in necrotic cells (42) (43) (44) . ␤-Gal is expressed in vitro in senescent cells (45) , and thus induced senescence is also a potential reason for nonspecific ␤-gal expression. There have been no reports investigating the induction of senescence-associated ␤-gal by radiation. In the absence of any other information, it seems likely that nonspecific staining in the pKZ1 mouse prostate after high-dose irradiation is related to a cell death process that will be equally applicable in transgenic and nontransgenic mouse tissues. Although the mechanisms underlying nonspecific ␤-gal staining in prostate are unknown, there appeared to be no adaptive response for nonspecific staining in the priming plus challenge groups (Table 1). Even though nonspecific staining may be a confounder for the magnitude of the adaptive response, a statistically significant adaptive response was still induced by all priming doses if nonspecific staining was not controlled for (P Ͻ 0.05, two-tailed Mann-Whitney U test).
There was no significant difference between the number of luminal cells screened in 50 prostate gland cross sections as a function of treatment, indicating that changes in the distribution of the number of inversions per gland cross section were the result of radiation treatment. Nonspecific staining in nontransgenic mouse prostate was again a potential confounder of the analysis of the distribution of inversions in gland cross sections; however, in nontransgenic mouse prostate, for doses of less than 1000 mGy, there were a maximum of two cells with nonspecific staining events in each gland cross section. This number was exceeded only in the 1000-mGy group, where a single gland cross section had three cells with nonspecific staining. It is possible that individual gland cross sections in transgenic mouse prostrate may contain both specific and nonspecific staining events. However, in transgenic mouse prostate, all or most of the staining events in gland cross sections with more than three events are likely to be the result of specific staining.
If the inversion frequency was increased when mice received a single radiation dose, then the maximum number of inversions per gland cross section was correspondingly increased, and when the inversion frequency was decreased, the maximum number of inversions per gland cross section was also reduced. In contrast, in the priming plus challenge groups, although there was an increase in the maximum number of inversions per gland cross section, there was not a corresponding increase in the inversion frequency. The difference between the distribution of inversions in prostate gland cross sections between two-dose and single-dose treatment groups allowed the generation of a hypothetical model of radiation damage responses (Fig. 4) . The type of damage response is based on the number of inversions per gland cross section. We propose two types of damage response, namely a low-dose inversion response (Fig. 4 , Response L), which is similar to the background radiation response, and a high-dose inversion response (Fig. 4 , Response H), which results from different biological pathways that require activation. After single low radiation doses of 10 mGy or less, we propose that the inversion frequency is the result of modulation of a constitutively active response, whereas after a high dose of 1000 mGy the chromosomal inversion response is due to both a constitutively active response and an induced response. This suggests that novel damage and/or repair pathways are activated after highdose irradiation. The distribution of inversions in prostate gland cross sections was similar in all priming plus challenge groups. The distribution of inversions across prostate gland cross sections suggests that the chromosomal inversion adaptive response is largely the result of modification or removal of the low-dose response to result in fewer inversions, because inversions induced by high doses remained in the presence of an adaptive response (Fig. 4 , Response H). The number of inversions resulting from the high-dose response was also reduced when an adaptive response was induced, but not to the same degree as was observed for the low-dose response. The net result of the reduction in both the low-dose and the high-dose inversion response was a reduction in the corrected inversion frequency in priming plus challenge groups to equal or less than the frequency in sham-treated mice.
The NEOTRANS 3 model was developed to predict and explain nonlinear responses for radiation-induced damage (46, 47) . NEOTRANS 3 was developed using data from the pKZ1 mouse spleen (21) and data on in vitro neoplastic transformation (13, 14, 19, 20) . Although NEOTRANS 3 was based on data from single radiation doses, the model has been used to predict adaptive responses for pKZ1 mouse chromosomal inversions in two-dose adaptive response studies (46) . Using NEOTRANS 3 , adaptive responses for chromosomal inversions in pKZ1 mouse prostate were predicted to be induced by the priming doses used here, although the predicted magnitudes were smaller than the observed magnitudes. The mechanisms underlying the adaptive response are currently unknown but are presumably the same for a single priming dose or if the priming dose is followed by a high challenge dose. It is known that DNA double-strand break repair is faster and more complete after priming plus challenge irradiation, which suggests a role for DNA repair in the adaptive response (48) . The underlying basis for the NEOTRANS 3 model is lowfidelity, error-prone DNA repair in cooperation with apoptosis in the ultra-low-dose region below 0.01 mGy and Trp53-dependent, high-fidelity DNA repair and apoptosis in cooperation with Trp53-independent protective apoptosis-mediated processes in the low-dose region around 1-10 mGy. The 1000-mGy challenge dose is hypothesized to further activate repair but not inhibit the low-dose processes, which act on high-dose radiation-induced damage and result in an inversion adaptive response. The adaptive responses observed here suggest that the net effect of the induced radioprotective mechanisms on subsequent highdose-induced chromosomal inversions in pKZ1 mouse prostate are similar in the 0.001-10-mGy priming dose range, although different priming doses may activate different types of repair. Studies on apoptosis and Trp53 expression at the low priming doses used here are required to substantiate the NEOTRANS 3 model, particularly for twodose adaptive response studies. Further investigation into the timing of adaptive responses at the 0.001-10-mGy doses is also required. The results presented here suggest that radioprotective factors are induced at biologically relevant doses. This finding is likely to have implications for radiation risk assessment and radiation safety and provides further evidence against the validity of the LNT model of risk assessment.
